<?xml version="1.0" encoding="UTF-8"?>
<results title="testTrace">
 <result pre="Original Article Potential drugâ€&quot;drug interactions in COVID 19 patients in" exact="treatment" post="with lopinavir/ritonavirâ˜†Interacciones medicamentosas potenciales en pacientes COVID 19 en"/>
 <result pre="COVID-19 resource centre remains active. Abstract Objectives To determine the" exact="prevalence" post="of potential interactions in COVID19 patients receiving lopinavir/ritonavir (LPV/r)."/>
 <result pre="over 18 years of age, admitted to hospital and under" exact="treatment" post="with LPV/r were included. A screening of potential interactions"/>
 <result pre="to hospital and under treatment with LPV/r were included. A" exact="screening" post="of potential interactions related to LPV/r and home and"/>
 <result pre="drugs prescribed (OR 4.33; 95% CI 2.40â€&quot;7.81; Pâ€¯=â€¯.000). Conclusion The" exact="prevalence" post="of potential interactions in COVD 19 patient undergoing treatment"/>
 <result pre="The prevalence of potential interactions in COVD 19 patient undergoing" exact="treatment" post="with LPV/r is high, with age (&amp;gt;65), ICU admission,"/>
 <result pre="there is no effective drug against COVID-19. One of the" exact="treatment" post="alternatives used is lopinavir/ritonavir (LPV/r), which showed in vitro"/>
 <result pre="which acts as a protease inhibitor (PI), used in the" exact="treatment" post="of human immunodeficiency virus (HIV) infection.4 Lopinavir has antiviral"/>
 <result pre="The main objective of the study was to determine the" exact="prevalence" post="and report the potential interactions in COVID-19 patients receiving"/>
 <result pre="15 days, from 20th March to 4th April 2020. The" exact="prevalence" post="of potential interactions in COVID-19 patients treated with LPV/r"/>
 <result pre="pneumonia due to COVID-19 or with clinical suspicion, who received" exact="treatment" post="with LPV/r, were included in the study. All cases"/>
 <result pre="hospital admission criteria, were considered as suspected COVID-19 patients. The" exact="diagnosis" post="of COVID-19 pneumonia was confirmed by positive PCR in"/>
 <result pre="LPV/r, with the concomitant administration of both. A review and" exact="screening" post="of the interactions between LPV/r, prescribed and home medication,"/>
 <result pre="361 patients with hospital admission secondary to COVID-19 pneumonia under" exact="treatment" post="with LPV/r were included in the analysis. 59.6% (nâ€¯=â€¯215)"/>
 <result pre="TdP: torsade de pointes; UGT: UDP-glucuronyl transferases. aRecommendations for concomitant" exact="treatment" post="with LPV/r. bAt therapeutic concentrations LPV/r does not inhibit:"/>
 <result pre="To our knowledge, no study has been published evaluating the" exact="prevalence" post="of potential drug interactions with LPV/r therapy. We are"/>
 <result pre="higher rate of potential interactions in the HIV population was" exact="treatment" post="with a boosted PI, with global prevalence between 27"/>
 <result pre="HIV population was treatment with a boosted PI, with global" exact="prevalence" post="between 27 and 40%.10, 11, 12 This difference can"/>
 <result pre="patients in our study had a cardiovascular history. This high" exact="prevalence" post="is explained by the fact that we include arterial"/>
 <result pre="fact that we include arterial hypertension within this group. COVID-19" exact="infection" post="is associated with haemostasis abnormalities, which may imply an"/>
 <result pre="azithromycin, drugs currently used in combination with LVP/r for the" exact="treatment" post="of COVID 19, also prolong QT, increasing the risk"/>
 <result pre="LPV/r (Table 3). Our study has some limitations. In the" exact="screening" post="of the interactions, we found slight discrepancies in some"/>
 <result pre="the other hand, databases report interactions between two drugs, while" exact="screening" post="is carried out with multiple combinations that can have"/>
 <result pre="pharmacodynamic interaction, prolongation of QT. In conclusion, COVID-19 patients undergoing" exact="treatment" post="with LPV/r are exposed to having a high prevalence"/>
 <result pre="undergoing treatment with LPV/r are exposed to having a high" exact="prevalence" post="of potential interactions, with age (&amp;gt;65), admission to the"/>
 <result pre="profile in a COVID-19 patient receiving LPV/r and his/her adequate" exact="treatment" post="can improve the safety and effectiveness of treatments. Collaboration"/>
 <result pre="and clinical pharmacists is essential for the comprehensive approach and" exact="treatment" post="of the COVID 19 pandemic. Conflict of interests The"/>
 <result pre="SARS coronavirus and MERS coronavirusâ€&quot;a possible reference for coronavirus disease-19" exact="treatment" post="optionJ Med Virol.92202055656310.1002/jmv.2572932104907 3CaoB.WangY.WenD.LiuW.WangJ.FanG.A trial of lopinavir-ritonavir in adults"/>
</results>
